Background
==========

The use of highly active antiretroviral therapy (HAART) has led to dramatic reductions in morbidity and mortality in HIV patients \[[@B1],[@B2]\]. However, tuberculosis (TB) remains a common opportunistic infections and a major cause of death among patients with HIV, especially in sub-Saharan African and Asian countries \[[@B3]-[@B5]\], where there is a high background prevalence of TB \[[@B5]-[@B7]\].

The risk of TB in HIV-infected patients and the impact of TB diagnosis on disease progression in HIV infected patients have been well described in Africa \[[@B3],[@B8]-[@B10]\]. The Asia-Pacific region has a large burden of both tuberculosis \[[@B7]\], with nearly 5 million prevalent cases and over 3 million new cases in 2006, and HIV, with an estimated 5 million people living with HIV and 380,000 new infections occurring in 2007 \[[@B11]\]. It is estimated that 2.5 million people are living with both infections in the region \[[@B5]\]. Despite the importance of these inter-related epidemics in the region, few studies have evaluated the risk of TB or its prognostic impact in patients with HIV \[[@B12]-[@B14]\].

Using data from The TREAT Asia HIV Observational Database (TAHOD), a multicentre prospective cohort study involving 17 clinical sites in the Asia-Pacific region, this paper aims to assess:

1\) The risk of, and factors associated with, TB diagnosis among TAHOD patients with prospective follow up;

2\) The prognostic significance of TB diagnosis on overall survival.

Methods
=======

TAHOD is a collaborative observational cohort study involving 17 sites in the Asia-Pacific region (See appendix). Detailed methods are published elsewhere \[[@B15]\]. Briefly, each site recruited 200 patients, including both patients on or not initiating HAART. Recruitment was based on a consecutive series of patients regularly attending a given site from a particular start-up time. Ethical approval for the study was obtained from the University of New South Wales Ethics Committee and respective local ethics committee.

The following data were collected: patient demographics and baseline data, CD4 and CD8 count, HIV RNA level, prior and new AIDS defining illness (ADI), date and cause of death, prior and current prescribed HAART, and reason for treatment change. Data are collected according to a common protocol. Upon recruitment, all available data prior to entry to TAHOD (considered as retrospective data) are extracted from patient case notes. Prospective data are updated six-monthly at each clinic and transferred to data management centre for aggregation and analyses. TAHOD sites are encouraged to contact patients who were not seen in the clinics in the previous 12 months.

TB diagnosis is defined as definitive when there is isolation (or culture) of *Mycobacterium tuberculosis*, *Mycobacterium bovis*or *Mycobacterium africanum*from a clinical specimen. TB is presumptively diagnosed when there is demonstration of acid-fast bacilli in a clinical specimen, or in a histopathological lesion when a culture is not available, in a person with signs or symptoms compatible with tuberculosis; or evidence of resolution of disease where treatment with two or more anti-tuberculosis medications have been prescribed and follow-up has been instigated.

Information on availability and regimen of TB treatment and prophylaxis were collected by surveying TAHOD sites. Anti-TB treatment is available to all HIV patients who are diagnosed with active TB in all participating TAHOD sites, with isoniazid, rifampicin, pyrazinamide and ethambutol given as intensive phase for at least 2 months, followed by isoniazid with either rifampicin or streptomycin or ethambutol as continuation phase for 4 to 10 months. TB prophylaxis is not available for patients at 13 of the 17 sites. For the 4 sites that provide prophylaxis, isoniazid is given for 6 to 12 months, to around less than 5% to 40% of the HIV patients, and is based on CD4 count (\<200 cells/μL), a positive tuberculin skin test or recent close contact with another patient with active tuberculosis.

TAHOD sites were grouped into two categories, high and low/intermediate TB burden, according to WHO TB reports \[[@B16]\]. The high TB burden group included sites from China, Cambodia, India, Indonesia, the Philippines and Thailand. The low/intermediate burden group included sites from Hong Kong, Taiwan, Malaysia, Singapore and Japan.

Patients who had at least one prospective follow-up visit after entry to TAHOD were included. Baseline characteristics were compared between patients with and without a prior TB diagnosis (a TB diagnosis within 7 days after entry to TAHOD). Factors associated with baseline TB were assessed using univariate and multivariate logistic regression models.

The risk of TB among patients with prospective follow up was assessed using the person-time method. Follow-up was censored at date of TB diagnosis, or death, or the date of the most recent visit. Predictors of TB diagnosis were assessed using Cox proportional hazards models. ADI (including TB) diagnosed within 7 days after entry to TAHOD were considered as pre-existing events (prior diagnoses). The first diagnoses of TB during prospective follow up were included, which also included the prospectively diagnosed TB among patients with prior TB.

Overall survival after entry to TAHOD was also assessed using the person-time method. Follow-up was from entry to TAHOD until date of death or censored at date of the most recent visit. Death was reported using standardised cause of death form and independently reviewed by a clinician in the data coordinating centre. TB was separated from the list of other ADIs in this analysis since the aim was to compare the impact on disease progression of TB diagnosis with other ADIs. Patient\'s disease stage was updated when CDC category B illness, TB, or any other ADI was diagnosed during follow up. Baseline TB and incident TB were included as time-dependent variables in assessing overall survival. Disease stage was categorised as \"CDC category A disease\", \"CDC category B disease\", \"TB only\", \"TB and CDC category B disease\", \"single non-TB ADI\", \"multiple non-TB ADIs\" and \"TB and other ADIs\". Cox proportional hazards models were used to assess risk factors associated with TB diagnosis and overall survival.

In analyses of TB incidence and overall survival, antiretroviral treatment and CD4 counts were fitted as time dependent variables. The observations of each patient were updated at each time when there was a treatment change or a new CD4 count. Antiretroviral therapy was included in the model following the intention to treat principle, and was categorised according to the duration on treatment. We included the time-updated HIV viral load in the final survival model, the coefficient of disease stage in predicting survival, which is our primary interest, remains almost identical. Due to concerns about the missing data and collinearity, we decided not to include HIV viral load in the model.

Analysis was performed using the statistical package STATA (StataCorp LP 2007, STATA 10 for Windows, College Station, Texas 77845 USA). Predictors were assessed using multiple logistic or Cox proportional hazards models with a forward stepwise approach. The final multivariate model included covariates that remained significant at the 0.05 level (2-sided). Non-significant variables were also presented and adjusted for final multivariate models.

Results
=======

By June 2007, a total of 3516 patients had been recruited to TAHOD, including 3279 (93%) patients with at least one prospective follow up. The overall follow up rate in TAHOD is 85%. At entry to TAHOD, 759 (of 3516, 22% of all patients) had prior diagnosis of TB, among whom 717 (of 3279, 22%) had at least one prospective follow up. Up to 90% of the patients had at least one CD4 test during follow up and the median number of CD4 tests in each patient was 4 (IQR 2 to 7). However, just 58% of the patients had at least one HIV viral load test and the median number of RNA test was 4 (IQR 2 to 5). 830 patients were not on HAART at baseline and 412 of them started treatment during follow up. Most patients were initiated with combination treatment with at least two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitors (73% of 2449 patients on treatment at baseline).

Baseline demographic characteristics are shown in Table [1](#T1){ref-type="table"}. Patients with prior TB were less likely to be female, more likely of age between 31 to 40 years (compared to age less than 30 years), less likely to report HIV infection through homosexual contact or injecting drug use (compare to heterosexual contact), more likely to have lower CD4 counts and have no HIV viral load tests, and more likely to receive antiretroviral treatment and come from countries with high TB burden.

###### 

Baseline characteristics associated with prior TB diagnosis

                                                                        Univariate   Multivariate                       
  -------------------------------------------------- ------ ----------- ------------ -------------- ------------------- ---------
  **Total**                                          3279   717 (22%)                                                   
  **Sex**                                                                                                               
  Male                                               2307   582 (25%)                                                   
  Female                                             972    135 (14%)   0.48         \<0.001        0.38 (0.30, 0.47)   \<0.001
  **Age (years)**                                                                                                       
  \< = 30                                            783    141 (18%)                                                   
  31\~40                                             1481   366 (25%)   1.49         \<0.001        1.39 (1.10, 1.76)   0.006
  41+                                                1015   210 (21%)   1.19         0.155          1.16 (0.89, 1.51)   0.261
  **Reported mode of infection**                                                                                        
  Heterosexual contact                               2288   584 (26%)                                                   
  Homosexual contact                                 614    66 (11%)    0.35         \<0.001        0.47 (0.34, 0.63)   \<0.001
  Injecting drug use                                 132    34 (26%)    1.01         0.952          0.73 (0.47, 1.12)   0.154
  Blood product                                      120    11 (9%)     0.29         \<0.001        0.29 (0.15, 0.56)   \<0.001
  Other/unknown                                      125    22 (18%)    0.62         0.049          0.60 (0.37, 0.98)   0.042
  **CD4 count at entry to TAHOD (cells/μL)**                                                                            
  \< = 50                                            241    84 (35%)                                                    
  51--100                                            209    78 (37%)    1.11         0.587          1.06 (0.74, 1.59)   0.780
  101--200                                           524    142 (27%)   0.69         0.029          0.71 (0.50, 1.00)   0.054
  201--300                                           578    121 (21%)   0.49         \<0.001        0.58 (0.41, 0.83)   0.003
  301+                                               1487   217 (15%)   0.32         \<0.001        0.42 (0.30, 0.58)   \<0.001
  Not tested                                         240    75 (31%)    0.85         0.401          0.91 (0.61, 1.38)   0.665
  **HIV viral load at entry to TAHOD (copies/mL)**                                                                      
  \< = 399                                           1133   188 (17%)                                                   
  400\~10,000                                        188    24 (13%)    0.74         0.187          0.93 (0.58, 1.50)   0.774
  10,001+                                            405    54 (13%)    0.77         0.123          0.92 (0.64, 1.32)   0.652
  No. not tested                                     1553   451 (29%)   2.06         \<0.001        1.36 (1.05, 1.76)   0.018
  **Antiretroviral treatment at entry to TAHOD**                                                                        
  No treatment                                       830    117 (14%)                                                   
  On treatment                                       2449   600 (25%)   1.98         \<0.001        1.99 (1.56, 2.56)   \<0.001
  **Country of TB burden**                                                                                              
  High                                               1990   547 (27%)                                                   
  Low/intermediate                                   1289   170 (13%)   0.40         \<0.001        0.55 (0.42, 0.70)   \<0.001

OR: odds ratio. CI: confidence intervals.

Among the 3279 patients with at least one prospective follow up, 135 patients developed TB, giving a TB incidence of 1.98 per 100 person-years (95% confidence interval \[CI\] 1.67--2.34). CD4 count at time of TB diagnosis was available in 83 patients, with a median 159 cells/μL (IQR 50 -- 261). Most of the TB diagnoses were definitive (92 of 135, 68%) or presumptive (30 of 135, 22%); there were 13 cases of possible TB (10%). However, no more information was collected in TAHOD regarding the availability of routine culture from the sites. Sites of TB infection were distributed as follows: pulmonary (60 of 135, 44%), extra-pulmonary (19 of 135, 14%), both pulmonary and extra-pulmonary TB (4 of 135, 3%) and unknown (52 of 135, 39%). The median TB incidence from the sites in low burden countries is 0.50 per 100 person years (IQR 0.46 to 0.57), while in high burden countries, 3.02 (IQR 0.98 to 4.85).

Factors associated with the rate of prospective TB diagnosis are presented in Table [2](#T2){ref-type="table"}. In multivariate models, factors remaining included younger age, lower recent CD4 count, duration of antiretroviral treatment, and living in high TB burden countries. Patients aged more than 40 years had significantly lower rate of TB diagnosis than that of patients aged 30 or younger (adjusted HR 0,47, p = 0.003). A higher CD4 count was associated with a significantly lower rate of TB diagnosis. Compared to patients who were not receiving antiretroviral treatment, there was a significant increase in the rate of TB diagnosis within 90 days after initiating treatment (adjusted HR 4.01, p = \< 0.001). The rate of TB diagnosis decreased continuously with the increase of duration of antiretroviral treatment. The rate of TB diagnosis was significantly lower among patients living in countries with low/intermediate TB burden than those in countries with high TB burden (adjusted HR 0.21, p = \< 0.001). Although prior TB diagnosis was associated with higher rate of prospective TB (p = 0.038), it lost statistical significance after adjustments.

###### 

Risk factors associated with TB diagnosis

                                                                            Univariate   Multivariate                       
  --------------------------------------------- ------ ------ ----- ------- ------------ -------------- ------------------- ---------
  **Total**                                     3279   6815   135   1.98                                                    
  **Sex**                                                                                                                   
  Male                                          2307   4883   100   2.05                                                    
  Female                                        972    1932   35    1.81    0.88         0.510          0.77 (0.52, 1.14)   0.198
  **Age at entry of TAHOD (years)**                                                                                         
  \< = 30                                       1103   2203   56    2.54                                                    
  31\~40                                        1401   2944   60    2.04    0.81         0.249          0.80 (0.56, 1.16)   0.237
  41+                                           775    1668   19    1.14    0.45         0.003          0.47 (0.28, 0.79)   0.005
  **Reported mode of infection**                                                                                            
  Heterosexual contact                          2288   4896   102   2.08                                                    
  Homosexual contact                            614    1243   16    1.29    0.62         0.074          1.29 (0.74, 2.23)   0.367
  Injecting drug use                            132    260    11    4.23    2.03         0.026          1.03 (0.54, 1.97)   0.917
  Blood products                                120    197    0     0.00    \-\--        \-\--          \-\--               \-\--
  Other/unknown                                 125    219    6     2.74    1.29         0.544          0.94 (0.41, 2.15)   0.877
  **CDC classification for HIV infection \***                                                                               
  Category A                                    1747   3497   48    1.37                                                    
  Category B                                    622    1158   39    3.37    2.42         \<0.001        1.33 (0.86, 2.05)   0.203
  Category C                                    1020   2160   48    2.22    1.62         0.017          1.37 (0.89, 2.10)   0.150
  **CD4 count (cells/μL) \***                                                                                               
  \< = 50                                       313    251    27    10.74                                                   
  51--100                                       312    222    15    6.74    0.64         0.162          0.69 (0.36, 1.29)   0.243
  101--200                                      928    842    30    3.56    0.34         \<0.001        0.41 (0.24, 0.69)   0.001
  201--300                                      1224   1250   23    1.84    0.17         \<0.001        0.21 (0.12, 0.37)   \<0.001
  301+                                          2225   4197   30    0.71    0.07         \<0.001        0.08 (0.05, 0.14)   \<0.001
  Not tested                                    68     53     10    18.98   1.83         0.106          1.02 (0.48, 2.15)   0.969
  **Prior TB diagnosis**                                                                                                    
  No                                            2562   5254   94    1.79                                                    
  Yes                                           717    1561   41    2.63    1.47         0.038          1.08 (0.74, 1.59)   0.684
  **Antiretroviral treatment \***                                                                                           
  No treatment                                  830    985    40    4.06                                                    
  Treated, 0\~90 days                           453    83     14    16.91   4.01         \<0.001        2.52 (1.31, 4.84)   0.006
  Treated, 91--180 days                         674    147    9     6.11    1.45         0.328          0.96 (0.45, 2.04)   0.909
  Treated, 181--360 days                        1017   414    5     1.21    0.30         0.013          0.24 (0.09, 0.62)   0.003
  Treated 361+ days                             2452   5186   57    1.29    0.30         \<0.001        0.40 (0.26, 0.61)   \<0.001
  **Country of TB burden**                                                                                                  
  High                                          1990   3644   115   3.16                                                    
  Low/intermediate                              1289   3171   20    0.63    0.21         \<0.001        0.28 (0.17, 0.45)   \<0.001

Rate: per 100 person years. HR: hazard ratio. CI: confidence interval.

\* Time dependent variable, patients can contribute person time to more than one category thus the sum of the categories may be more than the total number of patients.

A total of 142 deaths were recorded among 3279 patients during 6968 years of prospective follow up, a mortality rate of 2.04 per 100 person-years (95% CI 1.73--2.40). 69 deaths were reported to be directly related to HIV-associated illnesses (16 due to TB), 49 deaths due to other reasons, and cause of death was unknown for 24.

Factors associated with overall mortality are presented in Table [3](#T3){ref-type="table"}. In multivariate analysis, mortality was higher in patients aged more than 40 years, with lower CD4 counts and who were not receiving antiretrovirals. Mortality also appeared to worsen when CDC category B illness, TB, or any other ADI was diagnosed during follow up. Compared to patients with CDC category A disease only, mortality was greatest in patients with multiple ADIs other than TB (adjusted HR 2.27, p = 0.007) and patients with both TB and at least one other ADI (adjusted HR 2.12, p = 0.004).

###### 

Risk factors associated with overall survival

                                                                  Univariate   Multivariate                       
  ----------------------------------- ------ ------ ----- ------- ------------ -------------- ------------------- ---------
  **Total**                           3279   6968   142   2.04                                                    
  **Sex**                                                                                                         
  Male                                2307   4992   105   2.10                                                    
  Female                              972    1976   37    1.87    0.89         0.527          1.07 (0.73, 1.57)   0.732
  **Age at entry of TAHOD (years)**                                                                               
  \< = 30                             1103   2270   40    1.76                                                    
  31\~40                              1401   3016   50    1.66    0.95         0.812          0.86 (0.57, 1.32)   0.497
  41+                                 775    1682   52    3.09    1.78         0.006          1.79 (1.18, 2.71)   0.006
  **Reported mode of infection**                                                                                  
  Heterosexual contact                2288   5013   97    1.94                                                    
  Homosexual contact                  614    1261   12    0.95    0.47         0.014          0.68 (0.21, 1.25)   0.368
  Injecting drug use                  132    276    14    5.08    2.54         0.001          1.40 (0.27, 2.53)   0.772
  Blood products                      120    196    7     3.58    1.77         0.144          1.57 (0.26, 3.44)   0.721
  Other/unknown                       125    222    12    5.40    2.65         0.001          1.63 (0.12, 3.01)   0.883
  **CD4 count (cells/μL) \***                                                                                     
  \< = 50                             316    268    51    19.02                                                   
  51--100                             325    246    16    6.49    0.35         \<0.001        0.37 (0.21, 0.66)   0.001
  101--200                            939    875    20    2.29    0.12         \<0.001        0.14 (0.08, 0.24)   \<0.001
  201--300                            1238   1276   19    1.49    0.08         \<0.001        0.10 (0.06, 0.17)   \<0.001
  301+                                2242   4244   22    0.52    0.03         \<0.001        0.04 (0.02, 0.07)   \<0.001
  Not tested                          68     59     14    23.68   1.18         0.592          0.86 (0.46, 1.58)   0.622
  **Country of TB burden**                                                                                        
  High                                1990   3775   95    2.52                                                    
  Low/intermediate                    1289   3193   47    1.47    0.62         0.007          0.86 (0.60, 1.26)   0.435
  **Antiretroviral treatment \***                                                                                 
  No treatment                        830    1006   44    4.37                                                    
  Treated, 0\~90 days                 475    88     8     9.14    1.89         0.103          1.08 (0.50, 2.35)   0.846
  Treated, 91--180 days               703    154    5     3.24    0.67         0.405          0.39 (0.15, 0.99)   0.049
  Treated, 181--360 days              1048   428    21    4.91    1.06         0.838          0.73 (0.42, 1.27)   0.265
  Treated 361+ days                   2478   5292   64    1.21    0.31         \<0.001        0.32 (0.21, 0.51)   \<0.001
  **Disease stage \***                                                                                            
  CDC Category A                      1444   2900   37    1.28                                                    
  CDC Category B                      442    824    12    1.46    1.15         0.679          0.95 (0.49, 1.84)   0.886
  TB only                             328    634    13    2.05    1.65         0.122          1.53 (0.80, 2.91)   0.197
  TB + CDC Category B                 202    382    8     2.09    1.70         0.175          0.99 (0.45, 2.16)   0.976
  Single non-TB ADI                   523    1035   22    2.13    1.69         0.051          1.40 (0.80, 2.42)   0.237
  Multiple non-TB ADIs                212    461    19    4.12    3.34         \<0.001        2.27 (1.25, 4.10)   0.007
  TB and other ADI(s)                 336    732    31    4.23    3.57         \<0.001        2.12 (1.27, 3.55)   0.004

Rate: per 100 person years. HR: hazard ratio. CI: confidence interval. ADI: AIDS defining illness.

\* Time dependent variable, patients can contribute person time to more than one category thus the sum of the categories may be more than the total number of patients.

After fitting the Cox proportional hazards models, further testing of coefficients found that the mortalities were similar between patients with CDC category A and with B illness only (p = 0.433); among patients with TB only, with TB and CDC category B illness or with single non-TB ADI (p = 0.430); and between patients with multiple non-TB ADI and with TB and at least one other ADI (p = 0.410). Table [4](#T4){ref-type="table"} summarises the adjusted hazard ratios of these disease stages, initially separated, and then aggregated. Compared to patients with CDC category A or B illness only, mortality was marginally higher in patients with single Non-TB ADI, or TB only (adjusted HR 1.35, p = 0.173) and highest in patients with multiple non-TB AIDS or both TB and other ADI (adjusted HR 2.21, p \< 0.001).

###### 

Adjusted hazard ratios of disease stages on overall survival

  Disease stage          Adjusted HR (95% CI)   p-value   Combined Disease stage                                  Adjusted HR (95% CI)   p-value
  ---------------------- ---------------------- --------- ------------------------------------------------------- ---------------------- ---------
  CDC Category A                                          CDC Category A or B                                                            
  CDC Category B         0.95 (0.49, 1.84)      0.886                                                                                    
                                                                                                                                         
  TB only                1.53 (0.80, 2.91)      0.197     TB only, or TB + CDC Category B, or Single non-TB ADI   1.35 (0.88, 2.07)      0.173
  TB + CDC Category B    0.99 (0.45, 2.16)      0.976                                                                                    
  Single non-TB ADI      1.40 (0.80, 2.42)      0.237                                                                                    
                                                                                                                                         
  Multiple non-TB ADIs   2.27 (1.25, 4.10)      0.007     Multiple non-TB ADIs, or TB and other ADI(s)            2.21 (1.43, 3.42)      \<0.001
  TB and other ADI(s)    2.12 (1.27, 3.55)      0.004                                                                                    

HR: hazard ratio. CI: confidence interval. ADI: AIDS defining illness.

Adjusted for age, CD4 count and antiretroviral treatments.

Discussion
==========

This study found a baseline prevalence of previous TB diagnosis of over 20% and a rate of prospective TB diagnosis during prospective follow up of 1.79 per 100 person-years. Prognosis following diagnosis of TB appeared to be no worse than following other ADI diagnoses.

We previously found \[[@B15]\] a higher prevalence of ADIs at study entry in TAHOD compared with cohorts in Western countries \[[@B17],[@B18]\]. Much of the disparity in the prevalence of pre-existing ADI between TAHOD and western cohorts can be attributed to tuberculosis. \[[@B18]-[@B20]\]. In this analysis, patients from countries with high TB burden had a baseline prevalence of prior TB diagnosis of 27% and an incidence during follow up of 3.02 per 100 patient years, consistent with high TB burden countries in Asia \[[@B21]\] and Africa \[[@B9],[@B22]\]. Although the prevalence of prior TB diagnosis in countries with low or intermediate TB burden was approximately half of that in countries with high TB burden countries in Asia, this risk was still higher than that seen in western cohorts \[[@B23],[@B24]\].

During follow up the rate of prospective TB diagnosis was associated with a lower recent CD4 count, but not disease stages according to CDC classification. This discordance could partly be explained by the non directional nature of disease staging. Patients with category C disease treated with HAART have a reduced risk of TB, which reflected in the increase of CD4 count, but the disease stage does not change. Nevertheless, these data illustrate the ubiquity of TB risk across all stages of HIV infection.

Prior TB has been reported to increase the risk of subsequent TB \[[@B25]\]. In this study, however, prior TB lost statistical significance after adjustment, which is similar to findings from Lawn et al \[[@B10]\]. According to TAHOD sites, anti-TB treatment is available to all HIV patients who are diagnosed with active TB, which might provide at least time-limited reduction in the risk of TB in HIV patients \[[@B26]\].

Following HAART initiation, the rate of TB diagnosis was highest within 90 days after treatment initiation. Previously we have reported the increased rate of AIDS diagnosis shortly after HAART initiation in TAHOD \[[@B27]\]. It is probably due to immune reconstitution syndrome \[[@B28],[@B29]\]; however, it is difficult in this observational setting to verify these cases with limited evidence collected. It could also be the fact that patients were generally more immune suppressed when HAART was initiated.

The rate of TB diagnosis decreased continuously with the increase of duration of antiretroviral treatment, but still above the estimated population incidence for the South-East Asian and Western Pacific regions \[[@B7]\]. This is consistent with the incomplete nature of TB-specific immune restoration \[[@B30]\] and emphasises the limitations of HAART in reversing the impact of the HIV epidemic on TB control \[[@B31]\]. HAART is usually commenced towards the end of a long period of increased TB risk \[[@B32]\] and although associated with a reduction in TB incidence, \[[@B3],[@B21],[@B23],[@B24],[@B33]\] this is off-set to some degree by increased survival and consequent longer period at risk. It is possible that further reductions in TB incidence during ART could be achieved through treatment of latent TB infection. Since only a small proportion of patients in TAHOD received isoniazid preventive therapy, its impact on the incidence of prospective TB diagnosis or interaction of effect with ART could not be assessed in this study.

In this cohort of patients with access to HAART when clinically indicated according to local treatment guidelines, there was a borderline significant increase in adjusted overall mortality, when comparing patients developing TB and no other ADI to those with no HIV-related illness. The adjusted hazard for death for patients developing TB only was similar to those developing other single AIDS defining illnesses, and when these groups were combined their risk of mortality was marginally different to patients with Category A or B disease. Similarly, in patients developing more than one ADI, TB seemed to carry a similar additional hazard of death as other ADIs. The data suggest that in a diverse population of people living with HIV in Asia with ready access to ART, the prognostic implication of active tuberculosis is more similar to other ADIs than CDC Category B disease. In individual patients, the prognostic utility of TB is limited by the wide spectrum of immunodeficiency present at the time of clinical presentation. Nevertheless, these data are consistent with consideration of TB as an indicator of a level of immunodeficiency for which initiation or change of ART is indicated in the absence of CD4 count.

A number of limitations should be considered when interpreting the above findings. Firstly, TAHOD is a newly established cohort with relatively small number of endpoints and prospective TB diagnosis. Thus statistical analyses have limited power to differentiate the prognostic significance of TB diagnosis, CDC stage B diagnosis and other ADIs. This also limited our ability to investigate the risk of TB by duration of HAART, HIV RNA level, treatment of latent TB or the prognostic significance of pulmonary versus extra-pulmonary disease. Secondly, TAHOD patients cannot be seen as entirely representative of HIV patients in the Asia-Pacific region as participating sites are generally urban referral centres. Thirdly, although the follow-up rate in TAHOD is satisfactory, ADI and other important events might be under-reported due to a patient not regularly visiting the clinics or if a patient dies. There may also be delay in reporting of AIDS diagnosis and death. And finally, CD4 counts and antiretroviral treatment are correlated; in particular, treatment leads to increases in CD4 count, has an impact on disease progression (CDC category) and so improves survival. The objective of this analysis was to estimate the role of TB on rate of death, and clearly treatment, CD4 count and CDC category are all confounders. The ARV treatment effects estimated from our models on the incidence of TB diagnosis and subsequent survival could indeed be biased as they are also adjusted for current and subsequent CD4 counts and CDC category.

However, the comparison of the effect of TB and other CDC category on survival should remain robust, and we believe should be adjusted for these factors. Specific modelling, such as marginal structural modelling \[[@B34]\] or G-estimation \[[@B35]\], which adjusts for the relationship between time-varying confounding factors and treatments, would need to be applied if the interest is to look at the effect of antiretroviral treatment on the development of TB and/or survival

Conclusion
==========

In conclusion, the diversity in rates of TB seen in TAHOD patients reflects the diversity in background population TB incidence seen across Asia-Pacific region. Risk of TB disease was also associated with increasing immunodeficiency and was only partly reduced by antiretroviral treatment. Following the diagnosis of TB, the prognosis appeared to be similar to that following a diagnosis of other AIDS defining illnesses. Competing interestsThe authors declare there are no competing interests.
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